Growth Opportunities in Synthetic Biology, AI Augmented Diagnostics, Microbiome Enablers, Biomarker Discovery and Lab Automation 2021 -…

Posted: November 21, 2021 at 9:15 pm

DUBLIN, November 19, 2021--(BUSINESS WIRE)--The "Growth Opportunities in Synthetic Biology, AI Augmented Diagnostics, Microbiome Enablers, Biomarker Discovery, and Lab Automation" report has been added to ResearchAndMarkets.com's offering.

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) focuses on microbiome-based technologies, such as high throughput isolation and culturing of microbes, microbial biomarker-based diagnostics, microbial single cell genomic analysis, and so on.

Recent advances in synthetic biology platforms along with developments in lab automation and microfluidics technologies, which are bolstering the field have also been covered. Innovations around artificial intelligence (AI) and machine learning (ML) augmented diagnostics have been highlighted, and this includes both image-based diagnostics and molecular diagnostics. Many of the innovations covered in this issue support new biomarker discovery and novel therapeutics development.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Key Topics Covered:

Innovations in Life Sciences, Health & Wellness

High-Throughput Microbial, Cultivation, Isolation and Screening Platform

Automation in Microbial Culture

Galt Inc. - Investor Dashboard

Noninvasive Colorectal Cancer Screening Testing

Detection of Colon Polyps Thorough Microbial Biomarkers

Metabiomics Corp. - Investor Dashboard

Microbiome Single-Cell Genomic Analysis

Therapeutics and Diagnostic Development Tool

Bitbiome Inc. - Investor Dashboard

Picodroplet Microfluidic Technology for Single-Cell Analysis

Acceleration of Antibody Discovery and Cell-Line Development Processes Through Picodroplet Technology

Sphere Fluidics - Investor Dashboard

Clostridium-Assisted Drug Development Platform Supports Oral Drug Delivery

The Engineered Strain of Clostridium Serves as a Live Biotherapeutic Product

Chain Biotechnology - Investor Dashboard

Xenonucleic Acid and Superbdna Technologies for Diagnostics

XNA and Superbdna Offer High Sensitivity and Specificity in Detection of Cancer and COVID-19

Diacarta - Investor Dashboard

Robotic Cloud Lab for Drug Discovery and Development

Robotic Cloud Labs Revolutionize the Scientists' Workday

Strateos - Investor Dashboard

Developing Personalized Medicine to Slow Cell Senescence

Cancer Biomarker Detection for Faster Diagnosis

Developing Targeted Protein Degradation Technology

Automated Library Preparation for Next-Generation Sequencing

Machine Learning and AI-Based Cardiovascular Imaging Solutions

AI and Big Data-Enabled Genomic Diagnostics Targeting Rare Diseases

Exosomes Characterization to Study Disease-Specific Biomarkers

Machine Learning-Enabled Mutation Calling to Detect Cancer

Companies Mentioned

Story continues

Bitbiome Inc.

Chain Biotechnology

Diacarta

Galt Inc.

Metabiomics Corp.

Sphere Fluidics

Strateos

For more information about this report visit https://www.researchandmarkets.com/r/btqnmd

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211119005345/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Visit link:
Growth Opportunities in Synthetic Biology, AI Augmented Diagnostics, Microbiome Enablers, Biomarker Discovery and Lab Automation 2021 -...

Related Posts